BioCentury | Oct 31, 2016
Finance

Quark’s global ambitions

...small seed fund. The seed fund’s size is not disclosed. Its investments included nanoparticle play Sitka Biopharma Inc....
BioCentury | Oct 20, 2016
Finance

3Q16 Public-Private Partnership Roundup

...lateral sclerosis (ALS), raised C$1.8 million ($1.4 million) in a seed funding round. April 2016 Sitka Biopharma Inc....
BioCentury | Dec 16, 2013
Company News

Sitka Biopharma, Centre for Drug Research and Development, University of British Columbia cancer news

...the commercialization vehicle for the non-profit Centre for Drug Research and Development, launched cancer company Sitka Biopharma...
...which is in preclinical testing for bladder cancer, was developed between CDRD and the university. Sitka Biopharma Inc....
BioCentury | Dec 9, 2013
Company News

Sitka Biopharma management update

Sitka Biopharma Inc. , Vancouver, B.C. Business: Cancer Hired: Sean Cunliffe as CEO WIR Staff cancer...
Items per page:
1 - 4 of 4
BioCentury | Oct 31, 2016
Finance

Quark’s global ambitions

...small seed fund. The seed fund’s size is not disclosed. Its investments included nanoparticle play Sitka Biopharma Inc....
BioCentury | Oct 20, 2016
Finance

3Q16 Public-Private Partnership Roundup

...lateral sclerosis (ALS), raised C$1.8 million ($1.4 million) in a seed funding round. April 2016 Sitka Biopharma Inc....
BioCentury | Dec 16, 2013
Company News

Sitka Biopharma, Centre for Drug Research and Development, University of British Columbia cancer news

...the commercialization vehicle for the non-profit Centre for Drug Research and Development, launched cancer company Sitka Biopharma...
...which is in preclinical testing for bladder cancer, was developed between CDRD and the university. Sitka Biopharma Inc....
BioCentury | Dec 9, 2013
Company News

Sitka Biopharma management update

Sitka Biopharma Inc. , Vancouver, B.C. Business: Cancer Hired: Sean Cunliffe as CEO WIR Staff cancer...
Items per page:
1 - 4 of 4